Evunzekibart - Alligator Bioscience
Alternative Names: ATOR-1017; Monospecific monoclonal IgG4 antibody - Alligator BioscienceLatest Information Update: 28 Feb 2025
At a glance
- Originator Alligator Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Sweden (IV, Infusion)
- 03 Feb 2025 Biotheus has been acquired by BioNTech
- 05 Oct 2023 Efficacy data from a phase I trial in Solid tumours released by Alligator Bioscience